Citations

Clear

3042 citation(s) found for "Kumar, S".

Socioeconomic and treatment-related determinants of long-term cancer survival: A population-based SEER outcomes analysis.
Sharma, Akhilesh, Mal, Madho, TUMMALA, NAYANIKA, Nimmagadda, Rithish , Keswani, Shiwani, Jawed, Inshal, Kumar, Love, Maroules, Micheal, Nookala, Vinod, Gondhi, Venkatesh, Jawed, Inshal , Kumar, Love, Nookala, Vinod

Mayo Clinic

Journal of Clinical Oncology | May 27, 2026 | Volume: 44 | Issue: 16_suppl | Pages: 11186-11186

10.1200/jco.2026.44.16_suppl.11186 Get It

11186 Background: Cancer survival is shaped by tumor biology, treatment access, and socioeconomic context, yet population-level quantification of long-term survival disparities related to chemotherapy use and income is limited. We assessed five-year cancer-specific survival across demographic, treatment, and socioeconomic strata in a national registry. Methods: We performed a retrospective, population-based survival analysis using the Surveillance, Epidemiology, and End Results (SEER) database. Cancer-specific survival was evaluated at 12, 24, 36, 48, and 60 months after diagnosis. Outcomes were stratified by sex, race, chemotherapy receipt, and area-level median household income categories. Survival estimates were summarized descriptively and visualized using time-to-event curves. Results: Overall cancer-specific survival declined progressively over five years, from ~84% at 12 months to ~58% at 60 months. Sex differences were minimal, with similar five-year survival among males and females (~57–58%). Racial disparities were substantial: Asian/Pacific Islander patients demonstrated the highest survival across follow-up, while Black and American Indian/Alaska Native patients had lower early survival and persistent gaps at five years. Patients with recorded chemotherapy use had improved survival compared with those without or with unknown chemotherapy status; 12-month survival was ~88% versus ~80%, and five-year survival was ~65% versus ~57%, respectively. A pronounced socioeconomic gradient was observed: individuals in areas with median household income ≥$120,000 had higher five-year survival (~67%), whereas those in areas with income < $40,000 had markedly lower survival (~52%). Conclusions: In this national registry analysis, both chemotherapy utilization and higher socioeconomic status were strongly associated with improved long-term cancer survival, whereas persistent racial and income-related disparities remained evident. These findings highlight ongoing inequities in access to oncologic care and support the need for targeted policy interventions and equity-focused treatment delivery models. Interpretation should account for limitations inherent to observational registry data and potential residual confounding.
Organ- and histology-specific molecular and immune landscape of metastatic breast cancer.
Deshmukh, Sachin Kumar, Fanucci, K., Oesterreich, Steffi, Wu, Sharon, Xiu, Joanne, Advani, Pooja , Coelho, P. Barreto, Schnitt, S J, Lin, Nancy, Tolaney, Sara M., Metzger, Otto, Sledge, George W., Jeselsohn, Rinath, Marta, Guilherme Nader , Deshmukh, Sachin Kumar , Lee, Adrian V. , Oesterreich, Steffi , Wu, Sharon , Xiu, Joanne , Coelho, Priscila Barreto, Lustberg, Maryam B. , Tolaney, Sara M. , Mayer, Erica L. , Metzger, Otto , Jeselsohn, Rinath

Mayo Clinic

Journal of Clinical Oncology | May 27, 2026 | Volume: 44 | Issue: 16_suppl | Pages: 1024-1024

10.1200/jco.2026.44.16_suppl.1024 Get It

1024 Background: Invasive lobular carcinoma (ILC) is a distinct breast cancer (BC) subtype with dissemination patterns differing from invasive breast carcinoma of no special type (IBC-NST). While genomic differences between ILC and IBC-NST have been described, the extent to which molecular and immune profiles vary by metastatic organ and histology is poorly characterized. Methods: We conducted a retrospective analysis to evaluate organ- and histology-specific molecular features of metastatic BC (mBC). Patients with metastatic IBC-NST or pure ILC underwent NGS (592, NextSeq; WES/WTS, NovaSeq; Caris Life Sciences). Tumor mutational burden (high ≥10 mut/Mb), PD-L1 expression (22C3), and immune cell fractions (RNAseq deconvolution, quanTIseq) were assessed. Analyses were restricted to sites with ≥10 biopsies per histology. Comparisons used chi-square or Mann–Whitney U tests with multiple testing correction (q < 0.05). Results: A total of 2645 mBC biopsies (605 ILC; 2040 IBC-NST) were analyzed (Table). In ILC, ERBB2 mut frequency differed by metastatic site (q<0.01), with higher prevalence in liver (32.7%) and lower in gastrointestinal (GI) lesions (3.7%). In IBC-NST, ESR1 and GATA3 mut and FGFR1 amplification were enriched in liver metastases, whereas PD-L1 expression was highest in skin (20.7%) and lowest in liver (5.0%). No organ-specific differences were observed for PIK3CA, AKT, PTEN, BRCA1/2 or RB1 . Across metastatic sites, both ILC and IBC-NST showed differences in B cells, macrophages (M1/M2), neutrophils, NK cells, dendritic cells, CD8+ T cells, and Tregs (all q < 0.05); CD4+ T-cell differences were observed only in IBC-NST (q = 0.002). In organ-specific ILC vs IBC-NST comparisons, CDH1 mut were more frequent in ILC across sites, along with higher PIK3CA mut in skin (ILC 51.3% vs IBC-NST 34.4%) and higher ERBB2 mut in liver (32.7% vs 3.3%), whereas a higher TP53 mut frequency was observed in IBC-NST in skin (28.5% vs 52.3%) and lymph nodes (LND) (23.5% vs 55.5%) (all q < 0.01). Conclusions: mBC exhibits marked organ-specific molecular and immune heterogeneity that differs by histology. These findings support histology- and site-aware interpretation of metastatic biopsies and may inform biomarker assessment and treatment decisions in advanced disease. BC-NST ILC Skin LND Bone Breast Liver Perit. CNS q-value Skin LND Bone Breast GI Liver GYN Perit. CNS q-value N (specimens) 785 401 109 361 220 15 44 - 172 84 62 56 56 54 43 37 11 - ERBB2 mut (%) 3.2 3.1 3.2 2.3 3.3 7.1 2.5 1.0 7.1 7.4 16.4 15.4 3.7 32.7 2.4 5.7 11.1 <0.01 ESR1 mut (%) 9.4 5.2 8.3 16.0 28.2 7.1 2.4 0.0 7.8 7.2 8.9 9.8 16.7 26.0 4.9 20.0 0.0 0.9 FGFR1 amp (%) 10.1 6.6 5.6 12.8 16.5 0.0 9.7 0.02 4.4 3.4 6.7 6.1 2.4 5.6 7.7 18.5 0.0 1.0 IHC-PD-L1 (%) 20.7 - 5.3 16.0 5.0 11.1 10.3 0.02 8.9 - 5.0 5.7 6.1 0.0 0.0 0.0 14.3 1.0 TMB-High (%) 10.7 10.1 8.8 8.8 8.5 14.3 21.4 0.8 27.6 11.0 19.6 28.0 11.3 19.6 9.8 32.4 22.2 0.8 Perit: peritoneum; CNS: central nervous system; GYN: genital tract.
LATS1/2-CD38 Metabolic Rewiring Links Senescence to Intraplaque Thrombosis
Kotla, Sivareddy , Ko, Kyung Ae , Chen, Weiqing , Samanthapudi, Venkata Subrahman K, Hoang, Oanh, Mejia, Gilbert F. , Li, Shengyu , Lee, Hani , Zhang, Angie, Cho, Min Soon , Schadler, Keri L., Rivera, Luis Antonio, Samperio, Kay Carlene Tavares, Kim, Jung Hyun , Mendoza, Keila Carolina Ostos , Mariscal-Reyes, Karla N., Deswal, Anita, Fujiwara, Keigi , Koutroumpakis, Efstratios, Gi, Young Jin , Pathania, Rajneesh , Morrell, Craig N. , Lorenzi, Philip L. , Tan, Lin, Mahmud, Iqbal, Chini, Eduardo N., Herrmann, Joerg , Vasquez, Hernan G., Shen, Ying H. , Martin, James F. , Xu, Haodong, Le, Nhat‐Tu , Zhang, Aijun , Hoang, O.N. , Kim, Jung Hyun , Lee, Jonghae , Chen, Weiqing , Samanthapudi, Venkata Subrahmanya Kumar , Hoang, Oanh , Mejia, Gilbert , Li, Shengyu , Lee, Hani , Zhang, Aijun , Cho, Min Soon , Schadler, Keri , Rivera, Luis Antonio , Kim, Jung Hyun , Ostos-Mendoza, Keila C , Deswal, Anita M , Cooke, John P , Fujiwara, Keigi , Palaskas, Nicolas L , Koutroumpakis, Efstratios , Gi, Young Jin , Morrell, Craig , Lorenzi, Philip L , Madhmud, Iqbal , Hanssen, Nordin M J , Afshar-Kharghan, Vahid , Hamilton, Dale J , Yvan-Charvet, Laurent , Chini, Eduardo Nunes , Herrmann, Joerg , Shen, Ying H , Martin, James F , Seeley, Erin , Burks, Jared K , Brookes, Paul S , Wang, Guangyu , Le, Nhat-Tu , Abe, Jun-Ichi , Kotla, Sivareddy , Lee, Jonghae , Imanishi, Masaki , Cooke, John P. , Tan, Lin, Hamilton, Dale J. , Chini, Eduardo N. , Wang, Guangyu

Mayo Clinic

Circulation Research | May 27, 2026 | Volume: 139 | Issue: 2 | Pages: No page available

10.1161/circresaha.125.327427 | PMID 42200276 Get It

BACKGROUND: Atherothrombosis, which underlies most acute coronary syndromes and is driven by intraplaque thrombosis, preferentially occurs in regions of disturbed blood flow (d-flow). Although LATS1/2 (large tumor suppressor kinases 1 and 2) are known regulators of endothelial mechanotransduction, the mechanisms by which d-flow connects endothelial senescence, proliferation, and intraplaque thrombosis remain poorly understood. METHODS: We investigated endothelial cell (EC)-specific roles of Lats1/2 using inducible EC-specific knockout mice in a partial carotid ligation model. Spatial multiomics of human and mouse plaques was performed using imaging mass cytometry, COMET sequential immunofluorescence, and spatial metabolomics. RESULTS: Tamoxifen-induced deletion of both Lats1 and Lats2 (homozygous) in ECs caused fatal edema and increased vascular permeability. In contrast, Lats1 het ( ± ) / Lats2 homo ( −/−) -EC-specific knockout mice survived and developed spontaneous atherothrombotic plaques with neovascularization. Spatial proteomics revealed that LATS1/2 loss induced a senescence-associated stemness phenotype driven by CD38 upregulation. Spatial metabolomics showed sulfite and taurine accumulation, indicating SUOX (sulfite oxidase) deficiency. CD38 suppressed SUOX, demonstrated a switch into the reverse mode of mitochondrial complex V, increased succinate dehydrogenase activity, and promoted ATP consumption. Despite ATP depletion, glutamate metabolism and the citric acid cycle flux increased, sustaining EC proliferation under energetic stress. This senescence-associated stemness state promoted both proliferation and senescence, leading to fragile, leaky neovessels and intraplaque thrombotic lesions. Pharmacological CD38 inhibition attenuated these phenotypes. Similar EC states were observed in human plaques. CONCLUSIONS: Loss of Lats1/2 in ECs induces a CD38-associated senescence-associated stemness-like phenotype that promotes intraplaque thrombosis through mitochondrial metabolic reprogramming, including changes consistent with reverse-mode operation of mitochondrial complex V. These findings define a mechanistic link between disturbed flow, endothelial metabolic reprogramming, and intraplaque thrombosis and hemorrhage.
Streamlining Diagnosis of Bardet–Biedl Syndrome: New Diagnostic Algorithm With Updated Criteria
Pomeroy, Jeremy , Richards, Jesse , Kumar, S, Queen, Katie E., Zaritsky, Joshua, Cramer, Carl H. , Traboulsi, Elias I., Scruggs, Brittni A. , Davis, Erica E. , Keifer, Ekaterina , McGibbon, Emma, Ogden, Timothy, Graaf, B. de, Hymers, Tonia, FORSYTHE, ELIZABETH, Beales, Philip , Pomeroy, Jeremy J , Kumar, Seema , Cramer, Carl H , Scruggs, Brittni A , Davis, Erica E , Keifer, Ekaterina , Beales, Philip , Sweeney, Brooke , Zaritsky, Joshua J. , Traboulsi, Elias I. , Ogden, Timothy, Graaf, Bendert De

Mayo Clinic

American Journal of Medical Genetics Part A | May 23, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1002/ajmg.a.70199 | PMID 42175648 Get It

ABSTRACT Considerable advances have been made in our understanding of Bardet–Biedl syndrome (BBS), particularly in its core clinical features and molecular genetics, warranting an update to the existing diagnostic criteria framework. Using a rigorous, evidence‐based, and consensus‐driven process, a multidisciplinary group of international experts and patient‐led organizations developed an updated diagnostic algorithm. This algorithm provides practical, updated guidance for clinicians, including a pathway for accurately incorporating genetic findings into the diagnostic process. We recommend that a clinical diagnosis requires either 4 major criteria or 3 major and 2 minor criteria. Revised major criteria are retinal dystrophy, obesity (or overweight in individuals < 2 years old), congenital anomalies of the kidney and urinary tract or chronic kidney disease, hypogonadism/genital anomalies, neurodevelopmental/neurocognitive manifestations, and postaxial polydactyly. The diagnosis can also be established with a positive genetic testing result in patients exhibiting ≥ 1 major criterion, provided that genetic findings should be interpreted in the context of the patient's clinical presentation, age, family history, and overlap with related ciliopathies. These consensus criteria offer a simple algorithm incorporating updated definitions for major and minor criteria and genetic testing to support a timely and accurate diagnosis of patients with BBS, inform genetic counseling, and potentially facilitate earlier access to treatment. Trial Registration: CRIBBS Registry; ClinicalTrials.gov : NCT02329210
Treatment of Multiple Myeloma: ASCO Living Guideline, Version 2026.1.1
Banerjee, Rahul , Cheung, Matthew C. , Derman, Benjamin, Messersmith, Hans , Bhella, Sita, Chmielewski, Cynthia, Ebraheem, Mohammad, Kennedy, C. Todd , Kumar, Shaji , Langerak, Alan, Mian, Hira , Seth, Rahul, Subramanian, Latha, Wildes, Tanya M., Zanwar, Saurabh , Zhuo, Ying, Derman, Benjamin A , Al Hadidi, Samer , Ebraheem, Mohammad S , Kennedy, C Todd , Kumar, Shaji K , Lipe, Brea , Mian, Hira , Riva, Eloisa , Usmani, Saad , Wildes, Tanya , Zanwar, Saurabh S , Hicks, Lisa K. , Messersmith, Hans , Banerjee, Rahul , Derman, Benjamin A. , Chmielewski, Cynthia, Langerak, Alan, Seth, Rahul, Usmani, Saad Z. , Wildes, Tanya M.

Mayo Clinic

Journal of Clinical Oncology | May 20, 2026 | Volume: 44 | Issue: 22 | Pages: No page available

10.1200/jco-26-01139 | PMID 42160714 Get It

This guideline has been updated. This ASCO Living Guideline is reviewed on an eight-week cycle. Please see the online dynamic version for the latest updates. Living guidelines are developed for selected topic areas with rapidly evolving evidence that drives frequent change in recommended clinical practice. Living guidelines are updated on a regular schedule by a standing expert panel that systematically reviews the health literature on a continuous basis, as described in the ASCO Guidelines Methodology Manual . ASCO Living Guidelines follow the ASCO Conflict of Interest Policy Implementation for Clinical Practice Guidelines . Living Guidelines and updates are not intended to substitute for independent professional judgment of the treating clinician and do not account for individual variation among patients. See appendix for disclaimers and other important information ( Appendix 1 and Appendix 2 ). Updates are published regularly and can be found on the ASCO Publications website .
C54-05 Risk Stratification Model to Identify Patients at Risk for Hospital Acquired Sepsis
Kumar, N R, Abramovich, S, Karanam, V, Tkach, D, Herasevich, V, Karanam, V., Herasevich, Vitaly

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | May 18, 2026 | Volume: 212 | Issue: Supplement_1 | Pages: No page available

10.1093/ajrccm/aamag162.6225 Get It

Abstract Rationale Per the 2021 Sepsis Campaign, it is recommended that hospitals use a performance improvement program for sepsis screening, utilizing machine learning to improve specificity. Around 20% of sepsis at the Mayo Clinic, Rochester site is hospital acquired. As inpatient sepsis is usually detected by extreme physiologic derangement or clinical concern, we seek to leverage risk factors beyond traditional SIRS and sepsis criteria to create a machine and deep learning based risk stratification model to improve the precision of sepsis monitoring. Methods We designed a retrospective observational case control study, including patients diagnosed with sepsis as an inpatient at the Mayo Clinic, Rochester hospital and compared them to patients without a sepsis diagnosis over the last 7 years. Sepsis diagnosis was labeled by a combination of sepsis ICD codes and initial lactate elevation. We excluded transfers from outside hospitals, direct admissions for sepsis and patients diagnosed with sepsis in the emergency department. Data was extracted using Mayo Data Explorer, and data preparation and validation were performed using JMP Statistical Software and Python libraries. Feature selection was critical as we examined all data from previous contacts with healthcare, environmental factors, and dynamic trends of inpatient objective data; amongst 5,000 options of lab tests and vital measurements, we selected near 100 to reduce model complexity. We used XG Boost to train our model with a baseline cohort of 100 sepsis patients and 1000 patients without sepsis. Results We created a model that categorically classified patients into three sepsis risk level profiles (low-risk, medium-risk, high-risk) with performance metrics of a specificity of 97%, sensitivity of 65% and area under the receiver operating characteristic curve of 95%. Amongst laboratory data, lactate and creatinine had the highest feature importance (figure below). Our model also identified variables with the least importance to further refine our architecture. Conclusions Our model is one of the first sepsis risk stratification models whose algorithm is optimized for non-ICU inpatient wards, while the majority of similar studies were conducted on ICU and emergency department patients due to limited data availability. The model’s high specificity will allow for earlier sepsis recognition. By including our full cohort of 7,500 patients with sepsis and 35,000 patients without sepsis, we hope to improve class imbalance and increase sensitivity. By integrating transformer architecture, we seek to eliminate variables of low significance to create a model with more practical use, while maintaining high specificity. This abstract is funded by: None
A37-07 Real-world Study of Clinical Characteristics of Patients With Pulmonary Arterial Hypertension
Thakur, T, Dubrock, H M, Kumar-M, P, Watzker, A, Krishnappa, P, Rajendran, P, Nadapurohit, S, Maron, J, Dalal, A A, Hemnes, A R, DuBrock, Hilary M. , Watzker, A.

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | May 18, 2026 | Volume: 212 | Issue: Supplement_1 | Pages: No page available

10.1093/ajrccm/aamag162.5508 Get It

Abstract Rationale Pulmonary hypertension (PH) is classified into five groups. Diagnosis requires multiple tests delaying treatment. This study compared patient and diagnostic characteristics for pulmonary arterial hypertension (PAH; Group 1 PH), Group 2-5 PH, and non-PH using machine-learning in an Electronic Health Record (EHR) dataset. This is novel as prior studies use claims data which may lack hemodynamic parameters. Methods This study analyzed adult patient records from a HIPPA-complaint EHR dataset from Mayo Clinic (2015-2024). Cohort definitions: PAH: right heart catheterization (RHC) data [mPAP&gt;20 mmHg, PVR&gt;2 WU, PCWP≤15 mmHg]; ≥2 PAH ICD diagnosis codes or positive natural language processing (NLP) sentiments separated by ≥ 30 days; and use of at least one PAH medication within six months after index date. Group 2-5 PH: RHC (mPAP&gt;20mmHg) and ICD codes or positive NLP sentiment separated by ≥ 30 days for corresponding PH subtype. Non-PH: mPAP ≤ 20 mmHg and/or TRV ≤ 2.8 m/s. Index was the earliest NLP or ICD for PAH, earliest RHC for group 2-5 PH and most recent TRV/ mPAP for the non-PH cohort. Clinical variables were analyzed one-year before study index acknowledging data missingness as a limitation of retrospective dataset studies. Results 593 PAH, 817 Group 2-5 PH (67% with group 2 PH), and 11,600 non-PH patients (1:10 propensity-matched) were identified. Age, race, and symptoms were similar across cohorts. PAH had the highest proportion of females (60%) [Group 2-5 PH (50%) and non-PH cohort (53%)]. Clinical characteristic comparison is presented in Table 1. Comorbidities differed across cohorts. RHC: As expected, compared to Group 2-5, the PAH cohort had higher mPAP and PVR and lower PCWP. confirming a distinctly pre-capillary profile. ECHO: Compared to Group 2-5 PH, the PAH cohort had more pronounced right ventricular (RV) pressure overload and dysfunction and more impaired RV longitudinal strain, while TAPSE was similar. At the same time, left heart structure was less affected in PAH compared to Group 2-5. Among laboratory tests, serum creatinine was higher in Group 2-5 and ANA was higher in PAH cohort. Compared to the no-PH cohort, PAH and Group 2-5 cohorts exhibited clinically non-normal RHC and ECHO findings. Conclusion Although symptoms and demographic characteristics were similar among patients with and without PAH, unique RHC, ECHO, laboratory profiles and comorbidities differentiated PAH patients. Screening techniques using these distinct profiles could be considered to facilitate earlier diagnosis and treatment of PAH in clinical settings. This abstract is funded by: Merck & Co., Inc., Rahway, NJ, USA
A24-10 A Machine Learning Framework for Early Recognition of Pulmonary Arterial Hypertension Using Electronic Health Record Data
Thakur, T, Hemnes, A R, Kumar-M, P, Watzker, A, Maron, J, Nadapurohit, S, Dubrock, H M, Watzker, A. , DuBrock, Hilary M.

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | May 18, 2026 | Volume: 212 | Issue: Supplement_1 | Pages: No page available

10.1093/ajrccm/aamag162.5486 Get It

Abstract Rationale Pulmonary arterial hypertension (PAH) is a rare and progressive disease, where the guideline-recommended diagnostic confirmation is via right heart catheterization (RHC). However, due to non-specific symptomology, patients often experience delays in diagnosis that potentially impact disease outcomes. We sought to develop a machine learning (ML) based approach for early and appropriate detection of PAH. Methods Three cohorts were derived from Mayo Clinic electronic health record (EHR): confirmed PAH (N = 1,169), No PH (N = 11,600) and Other PH (Group 2-5 PH, N = 817), based on 2022 ESC/ERS guidelines. The study index was defined as the earliest diagnosis dates for PH cohorts (PAH & Other PH) or the latest PH negative echocardiogram (ECHO) or RHC for the No-PH cohort. Patients included in the study had at least one symptom (dyspnea, fatigue, syncope, chest pain, or lower extremity swelling) within one year prior to the study index. A two-step sequential ML modelling strategy was applied: Step 1 differentiated PH (PAH + Other PH) from No PH and step 2 differentiated PAH from Other PH. Models were trained using a combination of structured data, unstructured clinical notes to detect symptoms using natural language processing and ECG waveforms captured one year prior to study index. Models were tested both with and without ECHO parameters. SHAP (SHapley Additive explanations) values were used to determine important features contributing to models (without ECG waveforms). Results Models including ECHO parameters performed better compared to those without (Figure 1). The top feature impacting model without ECHO parameters was dyspnea in the preceding three months followed by heart failure and systolic blood pressure for the PH vs no PH; and T wave peak in V1 and ANA level in PAH vs other PH cohort. The top feature impacting model with ECHO was tricuspid regurgitation velocity followed by heart failure and right atrial pressure for the PH vs no PH; and mean blood pressure and left ventricular diameter in the PAH vs other PH cohort. Figure 1: Model performance in the two-step sequential approach PR-AUC=Precision Recall-Area Under Curve Conclusion This study demonstrates that ML models can aid in the identification of PAH in symptomatic patient populations. While ECG can identify patients for further testing, ECHO can further increase the accuracy and the need to refer patients to RHC for confirming diagnosis of PAH. This abstract is funded by: Merck & Co., Inc., Rahway, NJ, USA
B29-13 Kisspeptin/KISS1R Activation Attenuates TGF-β1-induced Fibroblast-to-Myofibroblast Transition in Human Lung Fibroblasts
Rajarajan, D, Tesch, J, Kumar, A, Ramakrishnan, Y S, Pabelick, C M, Prakash, Y, Sathish, V, Tesch, Jacob , Pabelick, Christina M.

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | May 18, 2026 | Volume: 212 | Issue: Supplement_1 | Pages: No page available

10.1093/ajrccm/aamag162.431 Get It

Abstract Rationale Lung fibroblasts (FBs) play a pivotal role in airway remodeling in asthma. During profibrotic and inflammatory conditions, FB undergoes myofibroblast differentiation, which contributes to airway wall thickening, stiffness, and airflow obstruction. Myofibroblast differentiation is a process in which fibroblasts transform into highly contractile fibers in response to profibrotic mediators such as transforming growth factor-beta 1 (TGF-β1). This transition is characterized by increased production of alpha-smooth muscle actin (α-SMA), and the formation of actin stress fibers, which are crucial for contractile machinery. Our previous findings identified the important role of Kisspeptin/KISS1R (Kp/KISS1R) in airway smooth muscle remodeling. However, there is no information about the expression and function of Kp/KISS1R in the lung FB. This study investigates the expression of Kp/KISS1R in lung FB and their role in myofibroblast transition. Methods Primary human lung FBs were isolated from surgical lung resections (Mayo IRB-approved) and cultured in DMEM-high glucose medium with 10% fetal bovine serum and 1% antibiotic/antimycotic. Upon reaching ∼90% confluence, cells were serum-deprived and treated with kisspeptin-10 (Kp-10, 1 µM) in the presence or absence of TGF-β1 (10 ng/mL). Expression of Kisspeptin, KISS1R and α-SMA in FB cells were assessed by western blotting and confocal microscopy. FB filamentous (F)-actin formation was analyzed by staining with phalloidin. In addition, collagen gel contraction assays were performed to study fibroblast contractility. Results We found the ubiquitous expression of kisspeptin and KISS1R in human FB. Notably, we observed that KISS1R expression was significantly reduced in asthmatic FB compared to non-asthmatic FB cells. Consistent with this observation, exposure of profibrotic mediator TGF-β1 effectively reduced the expression of KISS1R in non-asthmatic FB. Furthermore, TGF-β1 exposure significantly increased the α-SMA expression in human FB cells, a myofibroblast marker. Treatment with Kp-10 significantly reduced TGF-β1-induced α-SMA expression in FB cells. TGF-β1 stimulation in human FB increased the F-actin formation. Kp-10 significantly attenuated TGF-β1-induced F-actin formation in FB cells. Additionally, chronic TGF-β1 exposure enhanced collagen gel contraction by FBs, while Kp-10 treatment effectively reduced this contraction. Conclusion This study demonstrates that activation of Kp/KISS1R signaling attenuates TGF-β1-induced myofibroblast differentiation in lung FB, suggesting KISS1R as a potential therapeutic target against airway remodeling. This abstract is funded by: NIH grant R01-HL146705 (Venkatachalem)
Addition of Metastasis-Directed Therapy to Standard of Care for Oligometastatic Disease: Primary Aggregated Analysis of All Baskets from the Phase II Randomized EXTEND Trial
Sherry, Alexander D. , Haymaker, C, Wang, S, Liu, S, Medina-Rosales, Marina Nayeli , Seo, Aaron, Reddy, Jay P. , Mayo, Lauren L., Pant, Shubham , Kovitz, Craig A., Ha, Chul S., Smith, BD, Gomez, Daniel, Cohen, Lorenzo , Tannir, Nizar, Corn, Paul G., Siddiqui, Bilal A. , Ludmir, Ethan B., Tang, Chad , Haymaker, Cara , Liu, Suyu , Haymaker, Cara , Wang, Shuqi , Liu, Suyu , Bathala, Tharakeswara K , Medina-Rosales, Marina N , Reddy, Jay P , Chun, Stephen G , Walker, Gary , Pant, Shubham , Zhao, Dan , Kovitz, Craig A , Smith, Benjamin D , Gomez, Daniel , Cohen, Lorenzo , Koong, Albert C , Reuben, Alexandre , Tannir, Nizar , Tran, Phuoc T , Siddiqui, Bilal A , Subudhi, Sumit Kumar , Msaouel, Pavlos , Ludmir, Ethan B , Tang, Chad , Sherry, Alexander D , Seo, Aaron , Hara, Kieko , Chun, Stephen G. , Mayo, Lauren L. , Zhao, Dan , Ramirez, David Luis , Ha, Chul S. , Corn, Paul Gettys , Msaouel, Pavlos , Ludmir, Ethan B.

Mayo Clinic

Journal of Clinical Oncology | May 16, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1200/jco-25-02856 | PMID 42142259 Get It

PURPOSE We tested the hypothesis that adding metastasis-directed therapy (MDT) to standard-of-care (SOC) systemic therapy improves progression-free survival (PFS) among patients with oligometastatic disease. METHODS EXTEND was a multicenter randomized phase II trial. Patients with 1-5 metastases were randomly assigned to MDT + SOC versus SOC in one of the six baskets (breast, pancreas, kidney, two prostate baskets, and an other basket) with basket-specific stratification and powering. PFS, the primary end point, was prespecified in the per-protocol set within each basket, across all baskets, and across all baskets excluding the prostate baskets. Exploratory end points included circulating tumor DNA (ctDNA) and immune profiling. RESULTS From 2018 through 2023, 521 patients were screened, 350 were randomly assigned, and 334 were analyzed per protocol (MDT + SOC, n = 166; SOC, n = 168). Radiotherapy was used as MDT for 98% of metastases (370/379). Overall, after a median follow-up of 53 months, PFS was improved with MDT + SOC (hazard ratio [HR], 0.54 [95% CI, 0.41 to 0.72], P < .001). Similarly, PFS was improved when excluding the prostate baskets (HR, 0.60 [95% CI, 0.40 to 0.89]). Within each basket, PFS superiority was identified for the pancreas, prostate, and other baskets, whereas the breast and kidney baskets were inconclusive. At enrollment, detectable ctDNA correlated with shorter PFS and survival; by contrast, ctDNA clearance 3 months postenrollment correlated with improved survival. MDT + SOC-induced systemic immune activation was most pronounced among baskets demonstrating PFS superiority. CONCLUSION The phase II EXTEND trial supports the addition of MDT to SOC for oligometastatic disease. Histology-specific efficacy signals were identified for phase III testing. Translational insights suggest the potential for optimizing the definition of oligometastasis using ctDNA and point to systemic immune responses as a possible mechanism of benefit from MDT.